| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Ayrton Capital LLC | 9.9% | $967,625 | 774,100 | Ayrton Capital LLC | 31 Dec 2024 |
As of 30 Sep 2025, 21 institutional investors reported holding 433,089 shares of PharmaCyte Biotech, Inc. - Common Stock, $0.0001 par value (PMCB). This represents 5.5% of the company’s total 7,819,192 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 77,687 | $56,247 | +$1,030 | $0.79 | 6 |
| 2025 Q3 | 433,089 | $419,852 | -$145,856 | $0.97 | 21 |
| 2025 Q2 | 576,518 | $632,075 | +$9,324 | $1.09 | 20 |
| 2025 Q1 | 567,925 | $709,896 | -$40,590 | $1.25 | 21 |
| 2024 Q4 | 600,363 | $934,297 | -$425,833 | $1.57 | 18 |
| 2024 Q3 | 825,883 | $1,577,017 | -$369,356 | $1.91 | 22 |
| 2024 Q2 | 1,031,877 | $2,021,917 | +$102,393 | $1.96 | 25 |
| 2024 Q1 | 977,850 | $2,316,963 | -$237,140 | $2.37 | 27 |
| 2023 Q4 | 1,088,077 | $2,346,525 | +$81,424 | $2.16 | 30 |
| 2023 Q3 | 1,142,619 | $2,398,467 | -$193,554 | $2.10 | 26 |
| 2023 Q2 | 1,212,969 | $3,468,135 | -$6,627,389 | $2.86 | 27 |
| 2023 Q1 | 3,527,248 | $10,221,132 | +$391,105 | $2.91 | 26 |
| 2022 Q4 | 3,389,769 | $9,926,381 | -$3,961,051 | $2.93 | 25 |
| 2022 Q3 | 4,982,224 | $11,958,562 | +$2,478,751 | $2.40 | 20 |
| 2022 Q2 | 3,920,473 | $8,791,587 | +$251,009 | $2.25 | 23 |
| 2022 Q1 | 3,839,715 | $8,829,603 | +$807,784 | $2.30 | 18 |
| 2021 Q4 | 3,468,161 | $8,671,655 | +$4,799,078 | $2.50 | 17 |
| 2021 Q3 | 1,395,416 | $4,423,831 | +$4,423,797 | $3.17 | 15 |